Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations

Diagnostic Cytopathology

Volumn 39, Issue 6, 2011, Pages 395-401

  Ikeda, Katsuhide ^a   Tate, Genshu ^a   Suzuki, Takao ^a   Kitamura, Takashi ^a   Mitsuya, Toshiyuki ^a  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

effusion cytology; EMA; GLUT 1; immunocytochemistry; IMP3

Indexed keywords

EPITHELIAL MEMBRANE ANTIGEN; GLUCOSE TRANSPORTER 1; PROTEIN IMP3; RIBONUCLEOPROTEIN; SOMATOMEDIN B; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; ASCITES; CANCER CELL; CELL DIFFERENTIATION; CYTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MESOTHELIUM CELL; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ASCITIC FLUID; CARCINOMA, SQUAMOUS CELL; CELL SEPARATION; DIAGNOSIS, DIFFERENTIAL; EPITHELIAL CELLS; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; MUCIN-1; PLEURAL EFFUSION, MALIGNANT; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 79956105178     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21398     Document Type: Article

References (32)

1. Ikeda K, Tate G, Iezumi K, et al. Effusion cytomorphology and immunocytochemistry of malignant melanoma: Five cases of melanotic melanoma and one case of amelanotic melanoma. Diagn Cytopathol 2009; 37: 516-521.
2. Ikeda K, Tate G, Suzuki T, Mitsuya T,. Cytomorphologic features of immature ovarian teratoma in peritoneal effusion: A case report. Diagn Cytopathol 2005; 33: 39-42. (Pubitemid 40934421)
3. Ikeda K, Suzuki T, Tate G, Mitsuya T,. Cytomorphologic features of well-differentiated papillary mesothelioma in peritoneal effusion: A case report. Diagn Cytopathol 2008; 36: 512-515. (Pubitemid 351897381)
4. Politi E, Kandaraki C, Apostolopoulou C, et al. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol 2005; 32: 151-155. (Pubitemid 40256264)
5. Roberts F, Harper CM, Downie I, Burnett RA,. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: A study of thirteen antibodies. Am J Clin Pathol 2001; 116: 253-262. (Pubitemid 33044331)
6. Saleh HA, El-Fakharany M, Makki H, et al. Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: The utility of immunocytochemical panel in the differential dignosis. Diagn Cytopathol 2009; 37: 324-332.
7. Kim JH, Kim GE, Choi YD, et al. Immunocytochemical panel for distinguishing between adenocarcinoma and reactive mesothelial cells in effusion cell blocks. Diagn Cytopathol 2009; 37: 258-261.
8. Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005; 18: 105-110. (Pubitemid 40128102)
9. Yaziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: Identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006; 19: 514-523.
10. Hanna A, Pang Y, Bedrossian CW, et al. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. Diagn Cytopathol 2010; 38: 264-269.
11. Pu RT, Pang Y, Michael CW,. Utility of WT-1, p63. MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. Diagn Cytopathol 2008; 36: 20-25.
12. Wu GP, Zhang SS, Fang CQ, et al. Immunocytochemical panel for distinguishing carcinoma cells from reactive mesothelial cells in pleural effusions. Cytopathology 2008; 19: 212-217.
13. Dejmek A, Hjerpe A,. The combination of CEA. EMA, and BerEp4 and hyaluronan analysis specificity identifies 79% of all histologically verified mesotheliomas causing an effusion. Diagn Cytopathol 2005; 32: 160-166. (Pubitemid 40256266)
14. Ikeda K, Tate G, Suzuki T, et al. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: The expression profiles of IMP3/L523S in effusion cytology. Hum Pathol 2010; 41: 745-750.
15. Wolanski KD, Whitaker D, Shilkin KB, Henderson DW,. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer 1998; 82: 583-590. (Pubitemid 28112999)
16. Attanoos RL, Griffin A, Gibbs AR,. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor. P-glycoprotein and Bcl-2. Histopathology 2003; 43: 231-238. (Pubitemid 37115056)
17. Cury PM, Butcher DN, Corrin B, Nicholson AG,. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol 1999; 189: 251-257. (Pubitemid 29448921)
18. Shen J, Pinkus GS, Deshpande VD, Cibas ES,. Usefulness of EMA. GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol 2009; 131: 516-523.
19. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 2007; 20: 215-220. (Pubitemid 46422176)
20. Zimmerman RL, Goonewardene S, Fogt F,. Glucose transporter Glut-1 is of limited value for detecting breast carcinoma inserous effusions. Mod Pathol 2001; 14: 748-751. (Pubitemid 33069832)
21. Burstein DE, Reder I, Weiser K, et al. GLUT1 glucose transporter: A highly sensitive marker of malignancy in body cavity effusions. Mod Pathol 1998; 11: 392-396. (Pubitemid 28208103)
22. Afify A, Zhou H, Howell L, Paulino AF,. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids. Acta Cytol 2005; 49: 621-626. (Pubitemid 41667079)
23. Hanley KZ, Facik MS, Bourne PA, et al. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer 2008; 114: 49-56. (Pubitemid 351304612)
24. Ordonez NG,. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma: A review and update. Hum Pathol 2007; 38: 1-16. (Pubitemid 44880219)
25. King J, Thatcher N, Pickering C, Hasleton P,. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: A systematic review of published reports. Histopathology 2006; 49: 561-568. (Pubitemid 44924287)
26. Hunt JL, van de Rijn M, Gupta PK,. Immunohistochemical analysis of gel-transferred cells in cytologic preparations following smear division. Diagn Cytopathol 1998; 18: 377-380. (Pubitemid 28199075)
27. Gong Y, Joseph T, Sneige N,. Validation of commonly used immunostains on cell-transferred cytologic specimens. Cancer Cytopathol 2005; 105: 158-164. (Pubitemid 40868895)
28. Sherman ME, Jimenez-Joseph D, Gangi MD, Rojas-Corona RR,. Immunostaining of small cytologic specimens: Facilitation with cell transfer. Acta Cytol 1994; 38: 18-22. (Pubitemid 24054074)
29. Brown GC, Tao LC,. Restoration of broken cytology slides and creation of multiple slides from a single smear preparation. Acta Cytol 1992; 36: 259-263.
30. Cordell J, Richardson TC, Pulford KAF, et al. Production of monoclonal antibodies against human epithelial membrane antigen for use in diagnostic immunocytochemistry. Br J Cancer 1985; 52: 347-354. (Pubitemid 16217875)
31. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J,. Wide expression of the human erythrocyte glucose transporter Gult1 in human cancers. Cancer Res 1996; 56: 1164-1167. (Pubitemid 26065417)
32. Mueller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997; 14: 2729-2733. (Pubitemid 27283112)